Open Access Articles- Top Results for Neramexane


Systematic (IUPAC) name
Clinical data
219810-59-0 7pxY
PubChem CID 6433106
ChemSpider 4938294 7pxN
UNII 856DX0KJ84 7pxY
Chemical data
Formula C11H23N
169.307 g/mol
 14pxN (what is this?)  (verify)

Neramexane is a drug related to memantine,[1] which acts as an NMDA antagonist[2] and has neuroprotective effects.[3] It is being developed for various possible applications, including treatment of tinnitus,[4][5] Alzheimer's disease,[6] drug addiction[7] and as an analgesic.[8] Animal studies have also suggested antidepressant[9] and nootropic[10] actions, so there are a wide range of potential applications this drug may be used for. It also acts as a nicotinic acetylcholine receptor antagonist.[11]

A clinical trial found that doses of 50mg and above safely improved tinnitus scores over 16 weeks.[12]

See also


  1. ^ Gilling, K; Jatzke, C; Wollenburg, C; Vanejevs, M; Kauss, V; Jirgensons, A; Parsons, CG (2007). "A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization". Journal of Neural Transmission 114 (12): 1529–37. PMID 17728997. doi:10.1007/s00702-007-0792-7. 
  2. ^ Danysz, W; Parsons, CG; Jirgensons, A; Kauss, V; Tillner, J (2002). "Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists". Current Pharmaceutical Design 8 (10): 835–43. PMID 11945134. doi:10.2174/1381612024607117. 
  3. ^ Danysz, W; Parsons, CG (Mar 2002). "Neuroprotective potential of ionotropic glutamate receptor antagonists". Neurotoxicity Research 4 (2): 119–26. PMID 12829411. doi:10.1080/10298420290015872. 
  4. ^ Clinical trial number NCT00405886 for "Neramexane for Tinnitus" at
  5. ^ Clinical trial number NCT00739635 for "Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus" at
  6. ^ Rammes, G; Schierloh, A (Feb 2006). "Neramexane (merz pharmaceuticals/forest laboratories)". IDrugs 9 (2): 128–35. PMID 16523403. 
  7. ^ Kotlinska, J; Biala, G; Rafalski, P; Bochenski, M; Danysz, W (Oct 2004). "Effect of neramexane on ethanol dependence and reinforcement". European Journal of Pharmacology 503 (1-3): 95–8. PMID 15496302. doi:10.1016/j.ejphar.2004.09.036. 
  8. ^ Klein, T; Magerl, W; Hanschmann, A; Althaus, M; Treede, RD (Jan 2008). "Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia". European Journal of Pain 12 (1): 17–29. PMID 17449306. doi:10.1016/j.ejpain.2007.02.002. 
  9. ^ Kos, T; Legutko, B; Danysz, W; Samoriski, G; Popik, P (Sep 2006). "Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice". Journal of Pharmacology and Experimental Therapeutics 318 (3): 1128–36. PMID 16740621. doi:10.1124/jpet.106.103697. 
  10. ^ Zoladz, PR; Campbell, AM; Park, CR; Schaefer, D; Danysz, W; Diamond, DM (Oct 2006). "Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane". Pharmacology, Biochemistry and Behaviour 85 (2): 298–306. PMID 17045636. doi:10.1016/j.pbb.2006.08.011. 
  11. ^ Plazas PV, Savino J, Kracun S et al. (July 2007). "Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors". European Journal of Pharmacology 566 (1-3): 11–9. doi:10.1016/j.ejphar.2007.03.026. 
  12. ^ "A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus.". BMC Ear, Nose and Throat Disorders 11: 1. Jan 2011. PMID 21223542. doi:10.1186/1472-6815-11-1. 

Template:Navbox with collapsible sections

Lua error in package.lua at line 80: module 'Module:Buffer' not found.